Tofacitinib citrate
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Discoid Lupus Erythematosus
Conditions
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Trial Timeline
Apr 3, 2017 → Jun 10, 2020
NCT ID
NCT03159936About Tofacitinib citrate
Tofacitinib citrate is a phase 1 stage product being developed by Pfizer for Discoid Lupus Erythematosus. The current trial status is terminated. This product is registered under clinical trial identifier NCT03159936. Target conditions include Discoid Lupus Erythematosus, Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03159936 | Phase 1 | Terminated |
Competing Products
7 competing products in Discoid Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Secukinumab | Novartis | Phase 2 | 52 |
| Placebo + Daxdilimab | Amgen | Phase 2 | 51 |
| Etanercept | Pfizer | Phase 2 | 51 |
| Deucravacitinib + Placebo | Bristol Myers Squibb | Phase 2 | 51 |
| Belimumab 1 mg/kg + Belimumab 10 mg/kg | GSK plc | Pre-clinical | 22 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| R932333 + Placebo | Rigel Pharmaceuticals | Phase 2 | 44 |